Why the study?
COVID-19 utilizes the ACE2 pathway, and genetic variants influencing the renin-angiotensin-aldosterone system may contribute to observed heterogeneity in infection severity.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Variants in RAAS genes may stratify COVID-19 risk; leaves open any therapeutic role.
COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical comorbidities associated with the severity of infection suggest that possible variants known to influence the renin-angiotensin-aldosterone (RAAS) system pathway (particularly those that influence ACE2) may contribute to the heterogenous infection response. ACE2 and Ang(1-7) (the product of ACE2) seem to have a protective effect on the pulmonary and cardiac systems. Hypertension medication modulation, may alter ACE2 and Ang(1-7), particularly in variants that have been shown to influence RAAS system function, which could be clinically useful in patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: